STORM Therapeutics
About STORM Therapeutics
STORM Therapeutics is a Cambridge, UK-based biotechnology company focused on discovering and developing small molecule therapies that target RNA modifying enzymes involved in RNA epigenetics. The company aims to treat cancer and other diseases by inhibiting RNA modifications that drive cellular processes. It positions itself as a clinical stage biotech developing first-in-class inhibitors with a research emphasis on RNA-modifying enzymes as therapeutic targets.
Recent News
Storm Therapeutics Secures $56 Million Series C to Push METTL3 Cancer Drug Into Phase 2
STORM Therapeutics Raises €47.5 Million Series C to Harness the Power of RNA Modification to Treat Cancer
Follow the Money: Autoimmune, Inflammatory Disease Therapies, Antibody-Drug Conjugates, AKT1-Selective Inhibitor Programs
Kurma Partners Closes €215 Million Biofund IV to Back European BioTech Ventures From Paris